



PRESS RELEASE

February 2, 2018
Fuji Pharma Co., Ltd.

Alliance Ends for the Sale of OPTIRAY® Injection, MAGNESCOPE® Intravenous Injection and LIPIODOL® Injection

Fuji Pharma Co., Ltd. (Head office: Chiyoda-ku, Tokyo) and Guerbet Japan KK (Head office: Chiyoda-ku, Tokyo) reached an agreement today concerning the end of a licensing agreement that allowed Fuji Pharma to sell three pharmaceutical products in Japan. Based on this agreement, Fuji Pharma will stop selling these products on the days shown below and the products will be distributed exclusively by Guerbet Japan.

One of the three products is OPTIRAY® injection, a non-ionic contrast media. Fuji Pharma received the right to sell this product in December 2013 from a company then called Mallinckrodt Japan Co. Ltd. Fuji Pharma has been manufacturing and selling this contrast agent since receiving regulatory approval in June 2014. The other two products are MAGNESCOPE® intravenous injection, a macrocyclic MRI contrast agent, and LIPIODOL® injection, a contrast agent for imaging of the lymphatic system and uterus and fallopian tubes. Fuji Pharma has been selling these products since the company received the sales rights in October 2015.

In November 2015, Guerbet (Head office: Paris, France) acquired the contrast agent business of the Mallinckrodt Group to expand this business worldwide. At this time, Guerbet Japan has developed to the point where it is capable of selling contrast agents in Japan on its own. As a result, discussions took place between Fuji Pharma and Guerbet that led to an agreement to transfer sales of the three products to Guerbet Japan on the dates in the following table. The two companies will cooperate to be certain that the transfer is completed with no problems.

Discussions are under way concerning the timing of the transfer of regulatory approval to manufacture and sell OPTIRAY®. Fuji Pharma plans to continue manufacturing this product for the time being.

Although Fuji Pharma will no longer sell the three products, sales activities for the products have helped the company build relationships rooted in trust with medical institutions. Fuji Pharma is determined use these relationships in order to play an even greater role in Japan's health care sector by continuing to provide a reliable supply of generic contrast agents and other high-quality pharmaceuticals.

This change will have no impact on the consolidated results of operations for the fiscal year ending September 30, 2018.

Therapeutic category (generic name)	Product name	Date of change in distributor
Non-ionic contrast media (Ioversol)	OPTIRAY® injection	January 1, 2019
Macrocyclic MRI contrast agent (Meglumine gadoterate)	MAGNESCOPE® intravenous injection	October 2, 2018
Contrast agent for imaging of the lymphatic system and uterus/fallopian tubes Dilutant for pharmaceuticals and medical devices (Ethyl ester of iodinated poppy-seed oil fatty acid)	LIPIODOL® injection	October 2, 2018